Mainstream

MSCI beats Q2 top-line and bottom-line estimates; reaffirms FY25 outlook

MSCI beats Q2 top-line and bottom-line estimates; reaffirms FY25 outlook

Post ContentmsciRead More

You might also be interested in reading Prestige Consumer Healthcare outlines $1.1B-$1.115B FY26 revenue target amid Pillar5 acquisition and Clear Eyes supply recovery.

July 22, 2025
In Mainstream